Tafasitamab: First Approval - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/32946059/
Tafasitamab (tafasitamab-cxix; MONJUVI ® ) is an Fc-modified (i.e. two amino acid substitutions within the Fc region, resulting in increased Fcγ receptor affinity), humanized, anti-CD19 monoclonal antibody. Developed by MorphoSys...
-
Mark Fesler4yrThis anticd19 antibody is an exciting pairing with another immunotherapeutic, revlimid, and I would expect that this antibody will gain additional treatment partners and indications both in dlbcl and other Show More
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Source : https://doi.org/10.1080/14712598.2021.1884677
ABSTRACT Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) require further treatment options, especially in cases that cannot tolerate stem cell transplant or cytotoxic chemotherapy. CD19 has...
-
Mark Fesler4yrTafa and rev individually have low but respectable single agent activity in dlbcl that is enhanced significantly in combination and the dor is very exciting in a subset of patients Show More
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33299235/
Shallow-depth sequencing of cell-free DNA, a cheap and standardized approach to obtain molecular information on tumors non-invasively, is insufficiently explored for lymphoma diagnosis and disease follow-up. This study collected 318...
-
Mark Fesler4yrThis is exciting work. There are limitations to current diagnostic classification that may be overcome in the future by a greater reliance on molecular data Seems likely that Show More
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33230948/
Most patients with diffuse large B-cell lymphoma (DLBCL) are diagnosed at age 60 years or older. Challenges to effective therapy among older individuals include unfavorable biologic features of DLBCL, geriatric...
-
Mark Fesler4yrOutcomes in elderly dlbcl are worse than younger patients due to both both disease and patient characteristics. This review highlights present challenges but expresses hope for the future with Show More
Epstein-Barr virus-positive diffuse large B-cell lymphoma with human immunodeficiency virus mimicking complicated frontal sinusitis: A case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33728309/
Through this article, we suggest that EBV-positive DLBCL should be considered as possible diagnosis for patients with nonspecific space-occupying lesion of the paranasal sinuses. We also highlight an importance of...
-
Mark Fesler4yrEbv should not only be considered for dlbcl arising out of immunosuppression but also considered with head and neck predominant presentations of dlbcl In spite of ebv detection Show More